Immunogenomics papers: Difference between revisions
From genomewiki
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
** sequenced IGH-locus with BIOMED2 primers | ** sequenced IGH-locus with BIOMED2 primers | ||
* [http://www.ncbi.nlm.nih.gov/pubmed/8601832 Tomlinson 1996] | * [http://www.ncbi.nlm.nih.gov/pubmed/8601832 Tomlinson 1996] | ||
** Sanger sequencing of IGH | ** Sanger sequencing of <1000 IGH sequences | ||
** | ** compare germline mutations (=IMGT) versus somatic mutations | ||
** Where there is a little germline variation, they see many somatic mutations and the inverse | |||
* [http://www.pnas.org/content/106/48/20216 Glanville 2009, Pons lab, Pfizer] | * [http://www.pnas.org/content/106/48/20216 Glanville 2009, Pons lab, Pfizer] | ||
* [http://www.ncbi.nlm.nih.gov/pubmed/14636599 Zemlin 2003] | * [http://www.ncbi.nlm.nih.gov/pubmed/14636599 Zemlin 2003] | ||
Revision as of 22:05, 14 July 2011
- Boyd et al, Fire lab, Stanford
- sequenced IGH-locus with BIOMED2 primers
- Tomlinson 1996
- Sanger sequencing of <1000 IGH sequences
- compare germline mutations (=IMGT) versus somatic mutations
- Where there is a little germline variation, they see many somatic mutations and the inverse
- Glanville 2009, Pons lab, Pfizer
- Zemlin 2003
- CDR3 composition is very different between human and mouse
